BioSpace News Archive

Virios Therapeutics, Inc. today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share.

Inventiva announced that two scientific abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver on June 5-8, 2024 in Milan, Italy.

Aligos Therapeutics, Inc. today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Soleno Therapeutics, Inc. today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering.

Entero Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 2024, in San Diego, California.

Eupraxia Pharmaceuticals Inc. announced that it will host a virtual key opinion leader event on Wednesday, May 29, 2024, at 10:00 AM ET.

Covalon Technologies Ltd., an advanced medical technologies company, will release its Q2 Fiscal 2024 financial results on Wednesday, May 29, 2024, before markets open.

Moderna, Inc. announced that three abstracts on mRNA-4157, an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting, which will be held May 31 - June 4 in Chicago, IL.

MiNK Therapeutics, Inc. (NASDAQ: INKT) today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting.